Why Is Natera Stock Up Nearly 41% Since May?

NTRAYTD+25.9%SPYYTD+9.4%XLVYTD+22.9%
Analyze NTRA →

For questions about this article or underlying research, email help@trefis.com.

Natera (NTRA) stock rose 40.8% from May 20 to November 16, 2026, while the S&P 500 gained 0.3% over the same dates. The gain spans two quarterly reports from the company, which sells DNA tests used in cancer care, prenatal care and organ transplants, and the second, on November 5, came with a higher revenue forecast for the year. The shares jumped after the first report but fell after the second. So what did Natera report over those six months that buyers were paying for?

Image from Pixabay

What Did Natera Report Over Those Six Months?

Natera reported sales growth above 30% in both quarters and raised its outlook at the second report. On August 6, the company reported second-quarter revenue of $752.8 million, up 37.7% from a year earlier. The shares rose 21.4% the next day, their biggest one-day move between May and November.

Natera also gained ground in organ transplant testing. Medicare coverage for routine monitoring of transplant patients took effect on August 30. Management said on the third-quarter call that this had a positive impact on both volumes and prices.

On November 5, Natera reported third-quarter revenue of $794 million, up 34.1% from a year earlier. Management raised its revenue forecast for the year by about $140 million at the midpoint, to above $3 billion. It also set a goal to double revenue in three years, reaching $6 billion in 2029. Natera did not rise alone, though: Labcorp, a lab-testing peer with about five times Natera’s sales, gained 45.4% over the same dates.

How Far Have Natera’s Losses Narrowed?

Natera’s operating loss shrank to 9.0% of sales over the twelve months to September 30, 2026, from 16.6% in the twelve months before. That is the narrowest twelve-month loss margin at any quarter end in Natera’s record, which goes back to late 2016.

Natera kept up its sales growth while the loss narrowed, with revenue over the twelve months to September 30 reaching $2.91 billion, 37.4% more than in the twelve months before. A year earlier, twelve-month sales growth was 38.2%. That is what has changed in the business: Natera is growing at about the same rate while losing less on each dollar of sales.

Natera Still Reports An Operating Loss

Over the twelve months to September 30, that loss came to $260 million. Net income was also a loss, of $165 million, so a price-to-earnings ratio is not meaningful. At the November 16 close, investors valued the company at $41.6 billion. That is 14.3 times its sales, against 3.2 times for the S&P 500. Management said on the November 5 call that it expects to reach profitability if it executes its 2029 revenue plan.

Holders have already seen how fast the share price can move. The shares closed at $436 on October 29, their high for the past year. They then fell 14.6% on November 6, the day after the third-quarter report. Over the month to November 16, Natera stock lost 26.7%, against a 3.1% fall for the S&P 500.

Natera’s operating margin is the measure to watch at its next report, expected in February 2027.

Few owners saw either the August jump or the November drop coming. That is the point: no one can time news like that, and an owner of a single stock carries all of it.

Stop Guessing. Start Positioning.

No one can predict surprises like this one. The Trefis High Quality (HQ) Portfolio doesn’t try: it holds 30 quality stocks in equal weight, so no single surprise decides your result. Come see how it works.

See How HQ Works

Spot an error or want more like this? Tell us in 10 seconds.